Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 3;272(6):439.
doi: 10.1007/s00415-025-13179-w.

Inverse relation between serum neurofilament light chain and cognitive function in chronic inflammatory demyelinating polyneuropathy

Rohat Geran #  1 , Oliver L Steiner #  2   3   4 , Elena Krasivskaya  2 , Ulrike Hannemann  2 , Fabian Klostermann  2   3
Affiliations

Inverse relation between serum neurofilament light chain and cognitive function in chronic inflammatory demyelinating polyneuropathy

Rohat Geran et al. J Neurol. .

Abstract

Background: Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a dysimmune disease primarily targeting the Schwann cell myelin sheath in the peripheral nervous system (PNS), resulting in sensorimotor deficits. Surprisingly, subtle cognitive impairments as well as axonal damage, indicated by elevated serum neurofilament light chain (sNfL), prevail in CIDP. This study investigated whether elevated sNfL is associated with lower cognitive performance in CIDP.

Methods: Thirty-five CIDP patients underwent digital cognitive testing across multiple domains, alongside assessments of sociodemographic, clinical, and sNfL measures. Patients were stratified into low- and high-sNfL groups based on the median value, and clinical variables were compared. Further, general linear models, controlled for clinical and sociodemographic factors, were employed to evaluate the predictive value of sNfL for global and domain-specific cognitive functioning.

Results: Higher sNfL values were associated with worse general cognitive performance (β = -0.31, p = 0.016) and reduced processing speed (β = -0.40, p = 0.008). Patients with increased sNfL levels had a longer disease duration (p = 0.016), also linked to poorer cognitive outcome (β = -0.26, p = 0.045).

Conclusions: In this CIDP cohort, high sNfL levels were associated with reduced cognitive performance and longer disease duration. The findings suggest that sNfL is a clinical meaningful biomarker for the detection and monitoring of central involvement in the course of CIDP, a condition traditionally viewed as purely peripheral.

Keywords: CNS manifestations; Chronic inflammatory demyelinating polyneuropathy; Cognition; Neurodegeneration; SNFL.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflicts of interest: Fabian Klostermann received honoraria for lecturing and advisory activities, unrelated to the presented research, from Abbvie, Stadapharm, Esteve, CSL Behring, and Takeda. Consent for publication: Patients provided written consent for the publication of anonymization data.

Figures

Fig. 1
Fig. 1
Relationship between sNfL scores and A cognitive performance (expressed as z-scores) and B various clinical parameters. For all cognitive scores, the presented β and p values are derived from GLM models including age, depression, fatigue, disease duration, and motor symptoms as covariates. R-ODS Rasch-built overall disability scale, GLM generalized linear model, sNfL serum neurofilament light chain corrected for age and BMI, PIP posterior inclusion probability, BMA Bayesian model averaging
Fig. 2
Fig. 2
Comparison of sNfL z-scores across DSM-5–based cognitive impairment categories in CIDP patients. Categories include no/mild/mild-to-moderate/moderate neurocognitive disorder. sNfL values are presented as age- and BMI-adjusted z-scores. Error bars represent the standard error. *p ≤ 0.05, based on one-way ANOVA with Tukey’s post hoc test
See this image and copyright information in PMC

References

    1. Van den Bergh PYK, van Doorn PA, Hadden RDM, Avau B, Vankrunkelsven P, Allen JA et al (2021) European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision. Eur J Neurol 28(11):3556–3583. 10.1111/ene.14959 - DOI - PubMed
    1. Koike H, Nishi R, Ikeda S, Kawagashira Y, Iijima M, Katsuno M, Sobue G (2018) Ultrastructural mechanisms of macrophage-induced demyelination in CIDP. Neurology 91(23):1051–1060. 10.1212/wnl.0000000000006625 - DOI - PubMed
    1. Steiner OL, Klostermann F (2024) Central involvement in peripheral disease: melanopsin pathway impairment in chronic inflammatory demyelinating polyneuropathy. Brain Commun 6(4):fcae206. 10.1093/braincomms/fcae206 - DOI - PMC - PubMed
    1. Gable KL, Peric S, Lutz MW, Bozovic I, Petrovic M, Stojanov A et al (2022) A longitudinal evaluation of fatigue in chronic inflammatory demyelinating polyneuropathy. Brain Behav 12(8):e2712. 10.1002/brb3.2712 - DOI - PMC - PubMed
    1. Merkies IS, Kieseier BC (2016) Fatigue, pain, anxiety and depression in Guillain-Barré Syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Eur Neurol 75(3–4):199–206. 10.1159/000445347 - DOI - PubMed

MeSH terms

LinkOut - more resources